ACC・Amgen との連携プロジェクト

G2P-LIPID 試験


Implementation Science × Registry Based Clinical Trial

愛知医科大学 安藤博彦 On behalf of J-PCI Registry Committee

Conflict of interest: Hirohiko Ando

the Japanese Association of Cardiovascular Intervention and Therapeutics COI Disclosure


Proctoring Fee / Speaker Honoraria: Amgen, Terumo, Aboott



2024 ESC Guideline

Recommendations	Class ^a	Level ^b
Lipid-lowering treatment with an LDL-C goal of <1.4		
mmol/L (55 mg/dL) and a \geq 50% reduction in LDL-C	1	A
vs. baseline is recommended. ^{64,670,671}		


Guideline




2018 JCS Guideline

	推奨 クラス	エビデンスレベル
ストロング・スタチンを, 忍容可能な 最大用量で投与する 563-574)		A

Guideline





Registry-Based Clinical Trial


	Registry Study	Randomized Clinical Trial	Registry-Based Clinical Trial	
Enrollment				
Data Quality				
Bias				
Generalizability				
Cost				
Feasibility				

Registry-Based Clinical Trial

TASTE trial



Thrombus Aspiration during ST-Segment Elevation Myocardial Infarction



PATIENT POPULATION

We enrolled trial participants from the national comprehensive Swedish Coronary Angiography and Angioplasty Registry (SCAAR), which is part of the Internet-based Swedish Web System for Enhancement and Development of Evidence-based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) registry¹⁶ (see the Supplementary Appendix for details).



Implementation Science X Registry-Based Clinical Trial

G2P-LIPID trial

Guideline-to-Practice Implementation Trial for Lipid Management after PCI

- ✓ Implementation Science to Bridge G2P Gap
- ✓ J-PCI Registry—Based Clinical Trial
- ✓ Cluster Randomized Controlled Trial Design

Thank you



Hirohiko Ando anhiro@aichi-med-u.ac.jp